SCHEMBL4244499

SCHEMBL4244499

COc1cc(NC(=S)c2cc(Cl)c(Cl)s2)cc(OC)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ POLB P06746 1/20 0.40
▸ ALDH1A1 P00352 4/20 0.39
▸ GAA P10253 3/20 0.39
▸ MAPT P10636 3/20 0.39
▸ HPGD P15428 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ LMNA P02545 2/20 0.38
▸ ALOX12 P18054 2/20 0.38
▸ P2RX1 P51575 1/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4245262 0.82 RAB9A (0.56) RAB9AKMT2APOLBALDH1A1GAA
SCHEMBL1917833 0.77 MAPT (0.46) RAB9AKMT2APOLBALDH1A1GAA
SCHEMBL4738752 0.72 RAB9A (0.69) RAB9AKMT2AALDH1A1GAAMAPT
SCHEMBL1918608 0.68 RAB9A (0.52) RAB9APOLBALDH1A1GAAMAPT
SCHEMBL1886219 0.67 KMT2A (0.52) RAB9AKMT2APOLBALDH1A1GAA
SCHEMBL1918939 0.66 NPC1 (0.57) RAB9AKMT2AALDH1A1GAAMAPT
SCHEMBL1917679 0.66 MAPT (0.66) RAB9AKMT2APOLBALDH1A1GAA
SCHEMBL1917598 0.64 RAB9A (0.55) RAB9AKMT2AALDH1A1GAAMAPT
SCHEMBL12703093 0.63 RAB9A (0.53) RAB9AKMT2APOLBALDH1A1GAA
SCHEMBL4738754 0.61 KMT2A (0.39) RAB9AKMT2APOLBALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253685-A1 Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFICQUES 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253685-A1 Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent CDC25A, CDC25C, CDC25B RAB9A 874/4885KMT2A 1292/4885POLB 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback